Theraclion, a specialist in non-invasive ultrasound therapy, was boosted on the stock market on Tuesday by the announcement of positive results from its first study in the USA.

After jumping 27% in late morning trading, shares in the 'medtech' company - the originator of a robotic platform for treating varicose veins - were up over 10% by mid-day.

In a press release, the company states that the final results of the study show a feasibility rate, the trial's main endpoint, of 100%, while the diseased vein was treated in 95% of patients.

A total of 20 patients were followed up in this clinical trial approved by the US Food and Drug Administration (FDA) and conducted in New Jersey.

For Theraclion, these results represent an "important step" towards obtaining FDA approval for its "Sonovein" system, and access to the US varicose vein market.

Copyright (c) 2023 CercleFinance.com. All rights reserved.